Global Lung Cancer Therapeutics Market - 2025 -2033
Global Lung Cancer Therapeutics Market: Industry Outlook
The global lung cancer therapeutics market reached US$ 24.00 Billion in 2023, with a rise of US$ 25.92 Billion in 2024 and is expected to reach US$ 55.09 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
The global lung cancer therapeutics market is experiencing significant growth due to the increasing burden of lung cancer, the leading cause of cancer-related deaths worldwide. Factors such as smoking habits, air pollution, occupational hazards, and aging populations are contributing to this growth. The demand for innovative treatment options, including targeted therapies and immunotherapies, is increasing.
Pharmaceutical companies and research institutes are investing in R&D to discover new molecules, biomarkers, and gene-specific therapies to improve survival rates and quality of life. Governments and healthcare organizations are expanding lung cancer screening programs and enhancing access to treatment, particularly in high-incidence regions. The market is poised to benefit from personalized treatment solutions and next-generation therapeutics, transforming patient outcomes globally.
Global Lung Cancer Therapeutics Market Dynamics: Drivers & Restraints
Driver: Rising incidence of lung cancer
Lung cancer is the leading cause of cancer mortality globally. This trend is particularly alarming in emerging economies due to urbanization, industrialization, and tobacco use. As populations age, the risk of developing lung cancer increases, putting pressure on healthcare systems to develop effective and scalable treatment solutions.
The increasing number of cases has led to a demand for improved diagnostic tools and therapeutic interventions, prompting pharmaceutical companies to expand research into advanced treatment modalities. Public health awareness and government-backed initiatives to fund screening and early diagnosis programs contribute to market expansion. The need for timely and effective treatments is driving robust growth in the global therapeutics market. For instance, in 2024, lung cancer remains a significant global health concern, accounting for 12.4% of all new cancer cases and 1.8 million deaths annually, with approximately 2.5 million new cases reported.
Driver: Advancements in immunotherapy and targeted therapies
The use of immunotherapy and targeted therapies has significantly transformed the treatment of lung cancer, enhancing survival rates and quality of life. Traditional chemotherapy, which has limitations in efficacy and side effects, is still widely used. Immunotherapies like immune checkpoint inhibitors have shown success in recognizing and attacking cancer cells, leading to longer survival.
Targeted therapies, targeting specific genetic mutations, offer a personalized approach, minimizing harm to healthy cells and improving treatment outcomes. These therapies are particularly effective in non-small cell lung cancer (NSCLC), which accounts for most cases. The availability of genetic testing and biomarker identification has made personalized medicine a growing trend. The market is experiencing a surge in approvals and launches of novel agents, reshaping the commercial dynamics of the lung cancer therapeutics market.
Restraint: High cost of advanced therapies
The global lung cancer therapeutics market faces significant challenges due to the high cost of modern treatment options, particularly targeted therapy and immunotherapy. These therapies, while clinically effective, are financially burdensome for patients and healthcare systems, particularly in countries with limited reimbursement coverage. In the U.S., the cost of a full course of immunotherapy can be hundreds of thousands of dollars per year, making it inaccessible to many uninsured or underinsured patients.
The cost of diagnostic tests for targeted therapy, such as genomic profiling and biomarker testing, exacerbates the financial burden. Despite the potential benefits of generic drugs and biosimilars, the current market dynamics favor expensive branded drugs with limited competition, limiting patient access and hindering market penetration, especially in emerging markets.
Opportunity: Growth in early detection and liquid biopsy technologies
The lung cancer therapeutics market is experiencing a significant opportunity in the development and adoption of early detection technologies, particularly liquid biopsies and biomarker-based diagnostics. Early-stage lung cancer is often asymptomatic, leading to limited treatment options and high mortality rates. Advancements in molecular diagnostics and non-invasive testing methods, such as liquid biopsies, are paving the way for earlier and more accurate detection.
These technologies help identify lung cancer at a treatable stage, guide targeted therapies, and monitor treatment response. Companies investing in AI-driven screening tools and personalized biomarker panels are capitalizing on this unmet need. Governments and healthcare organizations are funding pilot programs and research initiatives to deploy these technologies at scale. As regulatory approvals increase and costs decrease, early detection tools are expected to become integral to lung cancer management.
Global Lung Cancer Therapeutics Market Segment Analysis
The global lung cancer therapeutics market is segmented based on disease type, treatment type, route of administration, distribution channel, and region.
Treatment Type:
The chemotherapy segment from the treatment type is expected to have 38.24% of the lung cancer therapeutics market share.
Chemotherapy remains a crucial part of lung cancer treatment, especially for advanced stages or those who cannot qualify for newer therapies. It is especially important for small cell lung cancer (SCLC), which is more aggressive and less responsive to targeted options. In many developing countries, chemotherapy remains the most accessible and cost-effective treatment option due to limited infrastructure and affordability constraints.
In developed nations, chemotherapy is often used in combination with immunotherapy and radiation to enhance therapeutic efficacy. The broad applicability of chemotherapy across different lung cancer stages and subtypes ensures continued demand for these agents. Research into optimizing dosing schedules, minimizing side effects, and improving combination therapies is helping to sustain its relevance.
For instance, Glenmark Pharmaceuticals launched Tevimbra, a lung cancer treatment drug developed by global oncology leader BeiGene, in India, marking its first foray into immune-oncology in the country. The approval from the Central Drugs Standard Control Organisation marks a significant milestone in the company's innovative oncology portfolio.
Global Lung Cancer Therapeutics Market - Geographical Analysis
The North America global lung cancer therapeutics market was valued at 10.91 Billion in 2024
North America leads the global lung cancer therapeutics market due to its advanced healthcare infrastructure, high awareness levels, and early adoption of innovative treatments. The US has a well-established regulatory environment, with the FDA fast-tracking the approval of breakthrough therapies and expanding indications for existing drugs.
Major pharmaceutical companies and research institutions foster an environment of continuous innovation, leading to a diverse pipeline of novel lung cancer therapies. Reimbursement policies, particularly under Medicare and private insurers, ensure patient access to high-cost treatments.
For instance, in May 2025, the FDA granted fast-track designation to ZL-1310, a promising new treatment for ES-SCLC patients, allowing the FDA to expedite the review process with Zai Lab, the drug's developer.
The Asia-Pacific global lung cancer therapeutics market was valued at 6.09 Billion in 2024
The Asia-Pacific region is experiencing a rapid growth in lung cancer therapeutics due to factors such as increased tobacco consumption, urban air pollution, and improved healthcare infrastructure. Countries like China, India, Japan, and South Korea are experiencing a surge in lung cancer cases, prompting governments to invest in awareness campaigns and screening programs. As healthcare access improves in rural and semi-urban regions, more patients are being diagnosed and treated, driving demand for both traditional and advanced therapeutics.
The rise of domestic pharmaceutical manufacturers and affordable generic drugs has made treatments more accessible to a broader population. Global pharmaceutical companies are also entering strategic partnerships with local players to tap into this underserved market. The region is also becoming a preferred destination for clinical trials due to its large patient pool, lower operational costs, and regulatory reforms.
For instance, in May 2025, Johnson & Johnson and Yuhan Corp. launched a chemo-free dual therapy for Japanese lung cancer patients with common EGFR mutations. The combination of Rybrevant and Yuhan's Lazcluze is intended for first-line treatment of unresectable, advanced, or recurrent NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
Global Lung Cancer Therapeutics Market – Major Players
The major players in the lung cancer therapeutics market include Pfizer, Merck & Co., Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Hoffmann-La Roche, and AbbVie, Inc., among others.
Global Lung Cancer Therapeutics Market – Key Developments
The global lung cancer therapeutics market is primarily driven by the rising global prevalence of lung cancer, advancements in immunotherapy and targeted therapies, and increasing awareness around early diagnosis. As healthcare systems continue to embrace precision medicine and adopt cutting-edge diagnostic tools, the market is expected to witness strong growth in the coming years.
The expanding elderly population, growing investments in oncology R&D, and favorable regulatory support further strengthen market potential. With a robust pipeline of next-generation therapies and increasing access in emerging economies, the market is poised for sustained expansion through 2033.
The global lung cancer therapeutics market report delivers a detailed analysis with 70 key tables, more than 61 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
The global lung cancer therapeutics market reached US$ 24.00 Billion in 2023, with a rise of US$ 25.92 Billion in 2024 and is expected to reach US$ 55.09 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
The global lung cancer therapeutics market is experiencing significant growth due to the increasing burden of lung cancer, the leading cause of cancer-related deaths worldwide. Factors such as smoking habits, air pollution, occupational hazards, and aging populations are contributing to this growth. The demand for innovative treatment options, including targeted therapies and immunotherapies, is increasing.
Pharmaceutical companies and research institutes are investing in R&D to discover new molecules, biomarkers, and gene-specific therapies to improve survival rates and quality of life. Governments and healthcare organizations are expanding lung cancer screening programs and enhancing access to treatment, particularly in high-incidence regions. The market is poised to benefit from personalized treatment solutions and next-generation therapeutics, transforming patient outcomes globally.
Global Lung Cancer Therapeutics Market Dynamics: Drivers & Restraints
Driver: Rising incidence of lung cancer
Lung cancer is the leading cause of cancer mortality globally. This trend is particularly alarming in emerging economies due to urbanization, industrialization, and tobacco use. As populations age, the risk of developing lung cancer increases, putting pressure on healthcare systems to develop effective and scalable treatment solutions.
The increasing number of cases has led to a demand for improved diagnostic tools and therapeutic interventions, prompting pharmaceutical companies to expand research into advanced treatment modalities. Public health awareness and government-backed initiatives to fund screening and early diagnosis programs contribute to market expansion. The need for timely and effective treatments is driving robust growth in the global therapeutics market. For instance, in 2024, lung cancer remains a significant global health concern, accounting for 12.4% of all new cancer cases and 1.8 million deaths annually, with approximately 2.5 million new cases reported.
Driver: Advancements in immunotherapy and targeted therapies
The use of immunotherapy and targeted therapies has significantly transformed the treatment of lung cancer, enhancing survival rates and quality of life. Traditional chemotherapy, which has limitations in efficacy and side effects, is still widely used. Immunotherapies like immune checkpoint inhibitors have shown success in recognizing and attacking cancer cells, leading to longer survival.
Targeted therapies, targeting specific genetic mutations, offer a personalized approach, minimizing harm to healthy cells and improving treatment outcomes. These therapies are particularly effective in non-small cell lung cancer (NSCLC), which accounts for most cases. The availability of genetic testing and biomarker identification has made personalized medicine a growing trend. The market is experiencing a surge in approvals and launches of novel agents, reshaping the commercial dynamics of the lung cancer therapeutics market.
Restraint: High cost of advanced therapies
The global lung cancer therapeutics market faces significant challenges due to the high cost of modern treatment options, particularly targeted therapy and immunotherapy. These therapies, while clinically effective, are financially burdensome for patients and healthcare systems, particularly in countries with limited reimbursement coverage. In the U.S., the cost of a full course of immunotherapy can be hundreds of thousands of dollars per year, making it inaccessible to many uninsured or underinsured patients.
The cost of diagnostic tests for targeted therapy, such as genomic profiling and biomarker testing, exacerbates the financial burden. Despite the potential benefits of generic drugs and biosimilars, the current market dynamics favor expensive branded drugs with limited competition, limiting patient access and hindering market penetration, especially in emerging markets.
Opportunity: Growth in early detection and liquid biopsy technologies
The lung cancer therapeutics market is experiencing a significant opportunity in the development and adoption of early detection technologies, particularly liquid biopsies and biomarker-based diagnostics. Early-stage lung cancer is often asymptomatic, leading to limited treatment options and high mortality rates. Advancements in molecular diagnostics and non-invasive testing methods, such as liquid biopsies, are paving the way for earlier and more accurate detection.
These technologies help identify lung cancer at a treatable stage, guide targeted therapies, and monitor treatment response. Companies investing in AI-driven screening tools and personalized biomarker panels are capitalizing on this unmet need. Governments and healthcare organizations are funding pilot programs and research initiatives to deploy these technologies at scale. As regulatory approvals increase and costs decrease, early detection tools are expected to become integral to lung cancer management.
Global Lung Cancer Therapeutics Market Segment Analysis
The global lung cancer therapeutics market is segmented based on disease type, treatment type, route of administration, distribution channel, and region.
Treatment Type:
The chemotherapy segment from the treatment type is expected to have 38.24% of the lung cancer therapeutics market share.
Chemotherapy remains a crucial part of lung cancer treatment, especially for advanced stages or those who cannot qualify for newer therapies. It is especially important for small cell lung cancer (SCLC), which is more aggressive and less responsive to targeted options. In many developing countries, chemotherapy remains the most accessible and cost-effective treatment option due to limited infrastructure and affordability constraints.
In developed nations, chemotherapy is often used in combination with immunotherapy and radiation to enhance therapeutic efficacy. The broad applicability of chemotherapy across different lung cancer stages and subtypes ensures continued demand for these agents. Research into optimizing dosing schedules, minimizing side effects, and improving combination therapies is helping to sustain its relevance.
For instance, Glenmark Pharmaceuticals launched Tevimbra, a lung cancer treatment drug developed by global oncology leader BeiGene, in India, marking its first foray into immune-oncology in the country. The approval from the Central Drugs Standard Control Organisation marks a significant milestone in the company's innovative oncology portfolio.
Global Lung Cancer Therapeutics Market - Geographical Analysis
The North America global lung cancer therapeutics market was valued at 10.91 Billion in 2024
North America leads the global lung cancer therapeutics market due to its advanced healthcare infrastructure, high awareness levels, and early adoption of innovative treatments. The US has a well-established regulatory environment, with the FDA fast-tracking the approval of breakthrough therapies and expanding indications for existing drugs.
Major pharmaceutical companies and research institutions foster an environment of continuous innovation, leading to a diverse pipeline of novel lung cancer therapies. Reimbursement policies, particularly under Medicare and private insurers, ensure patient access to high-cost treatments.
For instance, in May 2025, the FDA granted fast-track designation to ZL-1310, a promising new treatment for ES-SCLC patients, allowing the FDA to expedite the review process with Zai Lab, the drug's developer.
The Asia-Pacific global lung cancer therapeutics market was valued at 6.09 Billion in 2024
The Asia-Pacific region is experiencing a rapid growth in lung cancer therapeutics due to factors such as increased tobacco consumption, urban air pollution, and improved healthcare infrastructure. Countries like China, India, Japan, and South Korea are experiencing a surge in lung cancer cases, prompting governments to invest in awareness campaigns and screening programs. As healthcare access improves in rural and semi-urban regions, more patients are being diagnosed and treated, driving demand for both traditional and advanced therapeutics.
The rise of domestic pharmaceutical manufacturers and affordable generic drugs has made treatments more accessible to a broader population. Global pharmaceutical companies are also entering strategic partnerships with local players to tap into this underserved market. The region is also becoming a preferred destination for clinical trials due to its large patient pool, lower operational costs, and regulatory reforms.
For instance, in May 2025, Johnson & Johnson and Yuhan Corp. launched a chemo-free dual therapy for Japanese lung cancer patients with common EGFR mutations. The combination of Rybrevant and Yuhan's Lazcluze is intended for first-line treatment of unresectable, advanced, or recurrent NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
Global Lung Cancer Therapeutics Market – Major Players
The major players in the lung cancer therapeutics market include Pfizer, Merck & Co., Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Hoffmann-La Roche, and AbbVie, Inc., among others.
Global Lung Cancer Therapeutics Market – Key Developments
- In June 2025, Glenmark Pharmaceuticals launched Tevimbra, a lung cancer treatment drug developed by global oncology leader BeiGene, in India, marking its first foray into immune-oncology in the country. The approval from the Central Drugs Standard Control Organisation marks a significant milestone in the company's innovative oncology portfolio.
- In May 2025, Dana-Farber Cancer Institute researchers launched a first-of-its-kind study using a homegrown blood test to identify individuals at high risk of lung cancer who have never used tobacco. The team, led by principal investigator Narjust Florez, MD, is designed to address rising rates of lung cancer in younger people and prevalence in individuals of Asian or Hispanic/Latinx descent who have never used tobacco. The study aims to offer complimentary lung cancer screening to those who have never used tobacco.
The global lung cancer therapeutics market is primarily driven by the rising global prevalence of lung cancer, advancements in immunotherapy and targeted therapies, and increasing awareness around early diagnosis. As healthcare systems continue to embrace precision medicine and adopt cutting-edge diagnostic tools, the market is expected to witness strong growth in the coming years.
The expanding elderly population, growing investments in oncology R&D, and favorable regulatory support further strengthen market potential. With a robust pipeline of next-generation therapies and increasing access in emerging economies, the market is poised for sustained expansion through 2033.
The global lung cancer therapeutics market report delivers a detailed analysis with 70 key tables, more than 61 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Global Incidence of Lung Cancer
3.1.1.2. Advancements in Immunotherapy and Targeted Therapies
3.1.1.3. Government & Private Sector Support for Early Screening and Diagnostics
3.1.2. Restraints
3.1.2.1. High Cost of Advanced Therapies
3.1.2.2. Limited Access to Diagnostic Infrastructure in Emerging Markets
3.1.2.3. Drug Resistance and Tumor Heterogeneity
3.1.3. Opportunity
3.1.3.1. Growth in Early Detection Tools & Liquid Biopsy Technologies
3.1.3.2. Development of Biosimilars and Cost-Effective Therapies
3.1.4. Impact Analysis
4. GLOBAL LUNG CANCER THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Non-Small Cell Lung Cancer (NSCLC)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Small Cell Lung Cancer (SCLC)
6. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Paclitaxel (Taxol)
6.2.4. Albumin-bound paclitaxel (nab-paclitaxel, Abraxane)
6.2.5. Docetaxel (Taxotere)
6.2.6. Gemcitabine (Gemzar)
6.2.7. Others
6.3. Radiation Therapy
6.3.1. External Beam
6.3.2. Internal Beam
6.3.3. Proton Therapy
6.4. Targeted Therapy
6.4.1. Angiogenesis inhibitors
6.4.2. KRAS inhibitors
6.4.3. EGFR inhibitors
6.4.4. ALK inhibitors
6.4.5. ROSI inhibitors
6.4.6. Others
6.5. Immunotherapy
6.5.1. Pembrolizumab
6.5.2. Durvalumab
6.5.3. Nivolumab
6.5.4. Atezolizumab
6.5.5. Others
7. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous
8. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL LUNG CANCER THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Key Players
11.2. Pfizer*
11.2.1. Company Overview
11.2.2. Product Portfolio
11.2.2.1. Product Description
11.2.2.2. Product Key Performance Indicators (KPIs)
11.2.2.3. Historic and Forecasted Product Sales
11.2.2.4. Product Sales Volume
11.2.3. Financial Overview
11.2.3.1. Company Revenue
11.2.3.2. Geographical Revenue Shares
11.2.3.3. Revenue Forecasts
11.2.4. Key Developments
11.2.4.1. Mergers & Acquisitions
11.2.4.2. Key Product Development Activities
11.2.4.3. Regulatory Approvals, etc.
11.2.5. SWOT Analysis
11.3. Merck & Co
11.4. Amgen Inc.
11.5. AstraZeneca
11.6. Boehringer Ingelheim
11.7. Bristol-Myers Squibb Company
11.8. Novartis AG
11.9. Eli Lilly and Company
11.10. Hoffmann-La Roche
11.11. AbbVie, Inc (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Global Incidence of Lung Cancer
3.1.1.2. Advancements in Immunotherapy and Targeted Therapies
3.1.1.3. Government & Private Sector Support for Early Screening and Diagnostics
3.1.2. Restraints
3.1.2.1. High Cost of Advanced Therapies
3.1.2.2. Limited Access to Diagnostic Infrastructure in Emerging Markets
3.1.2.3. Drug Resistance and Tumor Heterogeneity
3.1.3. Opportunity
3.1.3.1. Growth in Early Detection Tools & Liquid Biopsy Technologies
3.1.3.2. Development of Biosimilars and Cost-Effective Therapies
3.1.4. Impact Analysis
4. GLOBAL LUNG CANCER THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Non-Small Cell Lung Cancer (NSCLC)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Small Cell Lung Cancer (SCLC)
6. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Paclitaxel (Taxol)
6.2.4. Albumin-bound paclitaxel (nab-paclitaxel, Abraxane)
6.2.5. Docetaxel (Taxotere)
6.2.6. Gemcitabine (Gemzar)
6.2.7. Others
6.3. Radiation Therapy
6.3.1. External Beam
6.3.2. Internal Beam
6.3.3. Proton Therapy
6.4. Targeted Therapy
6.4.1. Angiogenesis inhibitors
6.4.2. KRAS inhibitors
6.4.3. EGFR inhibitors
6.4.4. ALK inhibitors
6.4.5. ROSI inhibitors
6.4.6. Others
6.5. Immunotherapy
6.5.1. Pembrolizumab
6.5.2. Durvalumab
6.5.3. Nivolumab
6.5.4. Atezolizumab
6.5.5. Others
7. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous
8. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL LUNG CANCER THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Key Players
11.2. Pfizer*
11.2.1. Company Overview
11.2.2. Product Portfolio
11.2.2.1. Product Description
11.2.2.2. Product Key Performance Indicators (KPIs)
11.2.2.3. Historic and Forecasted Product Sales
11.2.2.4. Product Sales Volume
11.2.3. Financial Overview
11.2.3.1. Company Revenue
11.2.3.2. Geographical Revenue Shares
11.2.3.3. Revenue Forecasts
11.2.4. Key Developments
11.2.4.1. Mergers & Acquisitions
11.2.4.2. Key Product Development Activities
11.2.4.3. Regulatory Approvals, etc.
11.2.5. SWOT Analysis
11.3. Merck & Co
11.4. Amgen Inc.
11.5. AstraZeneca
11.6. Boehringer Ingelheim
11.7. Bristol-Myers Squibb Company
11.8. Novartis AG
11.9. Eli Lilly and Company
11.10. Hoffmann-La Roche
11.11. AbbVie, Inc (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Lung Cancer Therapeutics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Lung Cancer Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Lung Cancer Therapeutics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 10 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Lung Cancer Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Lung Cancer Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 18 North America Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Europe Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 South America Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 33 South America Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Pfizer: Overview
Table 42 Pfizer: Product Portfolio
Table 43 Pfizer: Key Developments
Table 44 Merck & Co: Overview
Table 45 Merck & Co: Product Portfolio
Table 46 Merck & Co: Key Developments
Table 47 Amgen Inc.: Overview
Table 48 Amgen Inc.: Product Portfolio
Table 49 Amgen Inc.: Key Developments
Table 50 AstraZeneca: Overview
Table 51 AstraZeneca: Product Portfolio
Table 52 AstraZeneca: Key Developments
Table 53 Boehringer Ingelheim: Overview
Table 54: Boehringer Ingelheim: Product Portfolio
Table 55: Boehringer Ingelheim: Key Developments
Table 56 Bristol-Myers Squibb Company: Overview
Table 57 Bristol-Myers Squibb Company: Product Portfolio
Table 58 Bristol-Myers Squibb Company: Key Developments
Table 59 Novartis AG: Overview
Table 60 Novartis AG: Product Portfolio
Table 61 Novartis AG: Key Developments
Table 62 Eli Lilly and Company: Overview
Table 63 Eli Lilly and Company: Product Portfolio
Table 64 Eli Lilly and Company: Key Developments
Table 65 Hoffmann-La Roche: Overview
Table 66 Hoffmann-La Roche: Product Portfolio
Table 67 Hoffmann-La Roche: Key Developments
Table 68 AbbVie, Inc: Overview
Table 69 AbbVie, Inc.: Product Portfolio
Table 70 AbbVie, Inc.: Key Developments
Table 1 Global Lung Cancer Therapeutics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Lung Cancer Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Lung Cancer Therapeutics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 10 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Lung Cancer Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Lung Cancer Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 18 North America Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Europe Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 South America Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 33 South America Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Lung Cancer Therapeutics Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Lung Cancer Therapeutics Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Lung Cancer Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Lung Cancer Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Lung Cancer Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Pfizer: Overview
Table 42 Pfizer: Product Portfolio
Table 43 Pfizer: Key Developments
Table 44 Merck & Co: Overview
Table 45 Merck & Co: Product Portfolio
Table 46 Merck & Co: Key Developments
Table 47 Amgen Inc.: Overview
Table 48 Amgen Inc.: Product Portfolio
Table 49 Amgen Inc.: Key Developments
Table 50 AstraZeneca: Overview
Table 51 AstraZeneca: Product Portfolio
Table 52 AstraZeneca: Key Developments
Table 53 Boehringer Ingelheim: Overview
Table 54: Boehringer Ingelheim: Product Portfolio
Table 55: Boehringer Ingelheim: Key Developments
Table 56 Bristol-Myers Squibb Company: Overview
Table 57 Bristol-Myers Squibb Company: Product Portfolio
Table 58 Bristol-Myers Squibb Company: Key Developments
Table 59 Novartis AG: Overview
Table 60 Novartis AG: Product Portfolio
Table 61 Novartis AG: Key Developments
Table 62 Eli Lilly and Company: Overview
Table 63 Eli Lilly and Company: Product Portfolio
Table 64 Eli Lilly and Company: Key Developments
Table 65 Hoffmann-La Roche: Overview
Table 66 Hoffmann-La Roche: Product Portfolio
Table 67 Hoffmann-La Roche: Key Developments
Table 68 AbbVie, Inc: Overview
Table 69 AbbVie, Inc.: Product Portfolio
Table 70 AbbVie, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Lung Cancer Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Non-Small Cell Lung Cancer (NSCLC) Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Small Cell Lung Cancer (SCLC) Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 11 Chemotherapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Radiation Therapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Targeted Therapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Immunotherapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 16 Oral Route of Administration in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Intravenous Route of Administration in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 19 Hospital Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Retail Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Online Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 23 North America Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 North America Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 25 North America Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 26 North America Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 27 North America Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 28 North America Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 31 Europe Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 Europe Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 33 Europe Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 34 Europe Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 35 Asia-Pacific Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 36 Asia-Pacific Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 37 Asia-Pacific Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 39 Asia-Pacific Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 43 South America Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 South America Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 45 South America Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 South America Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 47 Middle East and Africa Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 48 Middle East and Africa Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 49 Middle East and Africa Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 50 Middle East and Africa Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 51 Middle East and Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 52 Pfizer: Financials
Figure 53 Merck & Co: Financials
Figure 54 Amgen Inc.: Financials
Figure 55 AstraZeneca: Financials
Figure 56: Boehringer Ingelheim: Financials
Figure 57 Bristol-Myers Squibb Company: Financials
Figure 58 Novartis AG: Financials
Figure 59 Eli Lilly and Company: Financials
Figure 60 Hoffmann-La Roche: Financials
Figure 61: AbbVie, Inc.: Financials
Figure 1 Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Lung Cancer Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Non-Small Cell Lung Cancer (NSCLC) Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Small Cell Lung Cancer (SCLC) Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 11 Chemotherapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Radiation Therapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Targeted Therapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Immunotherapy Treatment Type in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 16 Oral Route of Administration in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Intravenous Route of Administration in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 19 Hospital Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Retail Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Online Pharmacies Distribution Channel in Global Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Lung Cancer Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 23 North America Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 North America Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 25 North America Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 26 North America Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 27 North America Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 28 North America Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 31 Europe Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 Europe Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 33 Europe Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 34 Europe Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 35 Asia-Pacific Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 36 Asia-Pacific Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 37 Asia-Pacific Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 39 Asia-Pacific Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 43 South America Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 South America Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 45 South America Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 South America Lung Cancer Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 47 Middle East and Africa Lung Cancer Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 48 Middle East and Africa Lung Cancer Therapeutics Market Share, By Type, 2024 & 2033 (%)
Figure 49 Middle East and Africa Lung Cancer Therapeutics Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 50 Middle East and Africa Lung Cancer Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 51 Middle East and Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 52 Pfizer: Financials
Figure 53 Merck & Co: Financials
Figure 54 Amgen Inc.: Financials
Figure 55 AstraZeneca: Financials
Figure 56: Boehringer Ingelheim: Financials
Figure 57 Bristol-Myers Squibb Company: Financials
Figure 58 Novartis AG: Financials
Figure 59 Eli Lilly and Company: Financials
Figure 60 Hoffmann-La Roche: Financials
Figure 61: AbbVie, Inc.: Financials
